Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
- Trial name
- NCT04580498
- Testing
- SHR-1701+Paclitaxel+carboplatin, SHR-1701
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer Stage III, Mutation
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- NUMER (NCT06563999)
- Testing
- Sunvozertinib, Crizotinib, Pralsetinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.
- Trial name
- NCT00791336
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01993810
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- Radiation Therapy Oncology Group
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00005838
- Testing
- shark cartilage extract AE-941, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small Cell Lung Cancer
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR).
- Trial name
- NCT05891080
- Testing
- Toripalimab, JS004, Pemetrexed
- Volunteers
- 124 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC, Locally Advanced Lung Carcinoma
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
The goal of this single arm, phase II clinical trial is to evaluate the efficacy and safety of cadonilimab (AK104) as induction and consolidation therapy in locally advanced/unresectable non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06448910
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Fudan University
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544648
- Testing
- carboplatin, nab-paclitaxel, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00020709
- Testing
- cisplatin, docetaxel, etoposide
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor over a shorter period of time may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00955175
- Testing
- hypofractionated radiation therapy
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- Cancer Trials Ireland
Non Small Cell Lung Cancer (NSCLC), Radical Treatment
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
For patients with stage III non-small cell lung cancer, which is radically treated, we will investigate whether prophylactic cranial irradiation (PCI) should become standard of care to prevent brain metastases.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Radical Treatment, Stage III Non-Small Cell Lung Cancer
- Trial name
- NVALT11 (NCT01282437)
- Testing
- Prophylactic Cranial Irradiation
- Where
- 9 sites in Netherlands
- Volunteers
- 315 people
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
- Trial name
- NCT00402883
- Testing
- Bevacizumab, Pemetrexed, Radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- SCRI Development Innovations, LLC
Unresectable Stage III Non-small-cell Lung Cancer
Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
For unresectable stage III (8th TNM) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial.
- Trial name
- NCT06591910
- Testing
- Chemoimmunotherapy, Surgery, Radiation
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281970
- Testing
- cisplatin, docetaxel, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small-Cell Lung Carcinoma
Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)
Locally advanced non-small cell lung cancer, NSCLC, (Stage III) is potentially curable with aggressive combined modality therapy (chemotherapy and radiation).
- Trial name
- NCT00136864
- Testing
- PET Diagnostic Imaging
- Where
- 5 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated radiation therapy when given together with chemotherapy in treating patients with stage III non-small cell lung cancer that cannot be removed by…
- Trial name
- NCT01486602
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
- Trial name
- NCT03840902
- Testing
- M7824, Durvalumab, Etoposide
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 153 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- ANVIL (NCT02595944)
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 884 sites in United States
- Volunteers
- 903 people
- Sponsor
- National Cancer Institute (NCI)